Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Naxitamab

    Client Email Product

    Naxitamab

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    0

    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    Listed Suppliers

    Listed Suppliers

    0

    API REF. PRICE (USD / KG)

    0

    API Market Place

    0

    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    1
    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    20
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Y-mAbs Therapeutics Naxitamab-gqgk Receives Suppl Approval in the U.S
    Y-mAbs Therapeutics Naxitamab-gqgk Receives Suppl Approval in the U.S

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761171

    FDA
    20 Mar 2024
    Share Share
    Y-mAbs DANYELZA for the Treatment of High-Risk Neuroblastoma approved in Brazil
    Y-mAbs DANYELZA for the Treatment of High-Risk Neuroblastoma approved in Brazil

    https://www.globenewswire.com/news-release/2023/05/23/2674387/0/en/Y-mAbs-DANYELZA-naxitamab-gqgk-for-the-Treatment-of-High-Risk-Neuroblastoma-approved-in-Brazil.html

    GLOBENEWSWIRE
    23 May 2023
    Share Share
    Y-mAbs Reports 1Q 2023 FYR and Recent Corporate Developments and Updates 2023
    Y-mAbs Reports 1Q 2023 FYR and Recent Corporate Developments and Updates 2023

    https://www.globenewswire.com/news-release/2023/05/08/2663801/0/en/Y-mAbs-Reports-First-Quarter-2023-Financial-Results-and-Recent-Corporate-Developments-and-Updates-2023-Financial-Guidance.html

    GLOBENEWSWIRE
    08 May 2023
    Share Share
    Y-mAbs and EMA Reach Agreement on the Pediatric Investigation Plan for Naxitamab
    Y-mAbs and EMA Reach Agreement on the Pediatric Investigation Plan for Naxitamab

    https://www.globenewswire.com/news-release/2023/02/02/2600538/0/en/Y-mAbs-and-the-European-Medicines-Agency-Reach-Agreement-on-the-Pediatric-Investigation-Plan-for-Naxitamab.html

    GLOBENEWSWIRE
    02 Feb 2023
    Share Share
    Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA
    Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA

    https://www.globenewswire.com//news-release/2022/12/21/2577938/0/en/Y-mAbs-Announces-Partnership-Regarding-Early-Access-Program-for-DANYELZA-naxitamab-gqgk-in-Europe.html

    GLOBENEWSWIRE
    21 Dec 2022
    Share Share
    Y-mAbs’ DANYELZA® for the Treatment of High-Risk Neuroblastoma Approved in China
    Y-mAbs’ DANYELZA® for the Treatment of High-Risk Neuroblastoma Approved in China

    https://www.globenewswire.com//news-release/2022/12/08/2570344/0/en/Y-mAbs-DANYELZA-naxitamab-gqgk-for-the-Treatment-of-High-Risk-Neuroblastoma-Approved-in-China.html

    GLOBENEWSWIRE
    08 Dec 2022
    Share Share
    Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
    Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

    https://www.globenewswire.com/news-release/2022/09/26/2522618/0/en/Y-mAbs-Announces-Regulatory-Filing-for-DANYELZA-naxitamab-gqgk-in-Brazil.html

    GLOBENEWSWIRE
    26 Sep 2022
    Share Share
    Y-mAbs's Naxitamab Chemoimmunotherapy Trial Meets Primary Endpoint
    Y-mAbs's Naxitamab Chemoimmunotherapy Trial Meets Primary Endpoint

    https://www.globenewswire.com/news-release/2022/05/26/2451583/0/en/Y-mAbs-Announces-Naxitamab-Chemoimmunotherapy-Investigational-Trial-for-High-Risk-Neuroblastoma-Meets-Primary-Endpoint.html

    GLOBENEWSWIRE
    26 May 2022
    Share Share
    Y-mAbs to Host Webinar on DANYELZA Frontline and HITS Data in Neuroblastoma
    Y-mAbs to Host Webinar on DANYELZA Frontline and HITS Data in Neuroblastoma

    https://www.globenewswire.com/news-release/2021/09/10/2295176/0/en/Y-mAbs-to-Host-Key-Opinion-Leader-Webinar-on-DANYELZA-naxitamab-gqgk-Frontline-and-HITS-Data-in-High-Risk-Neuroblastoma.html

    GLOBENEWSWIRE
    10 Sep 2021
    Share Share
    With pipeline setbacks mounting, United snares priority voucher formulation
    With pipeline setbacks mounting, United snares priority voucher formulation

    https://endpts.com/with-pipeline-setbacks-mounting-united-snares-priority-voucher-for-inhaled-formulation-of-pah-med-tyvaso/

    K. Blankenship ENDPTS
    29 Dec 2020
    Share Share
    Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk)
    Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk)

    https://www.globenewswire.com/news-release/2020/12/18/2147881/0/en/Y-mAbs-Signs-Distribution-Agreement-with-Swixx-for-DANYELZA-naxitamab-gqgk-and-Omburtamab-in-Eastern-Europe.html

    GLOBENEWSWIRE
    18 Dec 2020
    Share Share
    Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA®
    Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA®

    https://www.globenewswire.com/news-release/2020/12/18/2147881/0/en/Y-mAbs-Signs-Distribution-Agreement-with-Swixx-for-DANYELZA-naxitamab-gqgk-and-Omburtamab-in-Eastern-Europe.html

    GLOBENEWSWIRE
    18 Dec 2020
    Share Share
    Y-mAbs Takeda Announce Exclusive License and Distribution Agreement
    Y-mAbs Takeda Announce Exclusive License and Distribution Agreement

    https://www.streetinsider.com/Corporate+News/Y-mAbs+Therapeutics+%28YMAB%29%2C+Takeda+%28TAK%29+Announce+Exclusive+License+and+Distribution+Agreement+for+DANYELZA%C2%AE+%28naxitamab-gqgk%29+and+Omburtamab+in+Israel/17683384.html

    STREETINSIDER
    04 Dec 2020
    Share Share
    FDA grants accelerated approval to naxitamab for high-risk neuroblastoma
    FDA grants accelerated approval to naxitamab for high-risk neuroblastoma

    https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-naxitamab-high-risk-neuroblastoma-bone-or-bone-marrow

    FDA
    30 Nov 2020
    Share Share
    FDA Approves Naxitamab for Treatment of Relapsed High-Risk Neuroblastoma
    FDA Approves Naxitamab for Treatment of Relapsed High-Risk Neuroblastoma

    https://www.targetedonc.com/view/fda-approves-naxitamab-for-treatment-of-relapsed-refractory-high-risk-neuroblastoma

    Nichole Tucker TARGETEDONC
    27 Nov 2020
    Share Share
    Y-mAbs Danyelza (Naxitamab-gqgk) Receives Supplemental Approval In US
    Y-mAbs Danyelza (Naxitamab-gqgk) Receives Supplemental Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761171

    FDA
    26 Nov 2020
    Share Share
    Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma
    Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma

    https://www.globenewswire.com/news-release/2020/10/16/2109854/0/en/Y-mAbs-Announces-Update-on-Naxitamab-and-Omburtamab-in-Neuroblastoma.html

    GLOBENEWSWIRE
    16 Oct 2020
    Share Share
    Y-mAbs Announces USFDA Acceptance of Biologics License Application for Danyelza
    Y-mAbs Announces USFDA Acceptance of Biologics License Application for Danyelza

    https://www.globenewswire.com/news-release/2020/06/02/2042283/0/en/Y-mAbs-Announces-U-S-FDA-Acceptance-of-Biologics-License-Application-for-Danyelza-naxitamab-for-the-Treatment-of-Neuroblastoma-for-Priority-Review.html

    GLOBENEWSWIRE
    01 Jun 2020
    Share Share
    Y-mAbs' naxitamab shows positive effect in neuroblastoma study
    Y-mAbs' naxitamab shows positive effect in neuroblastoma study

    https://seekingalpha.com/news/3509713-y-mabs-naxitamab-shows-positive-effect-neuroblastoma-study

    Douglas W. House SEEKINGALPHA
    25 Oct 2019
    Share Share
    Y-mAbs ramps up head count in post-IPO hiring spree
    Y-mAbs ramps up head count in post-IPO hiring spree

    https://www.fiercebiotech.com/biotech/y-mabs-ramps-up-headcount-post-ipo-hiring-spree

    Nick P.Taylor FIERCE BIOTECH
    15 Aug 2019
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search